|Previous Section||Index||Home Page|
The gross deficit is forecast to reduce in 2006-07 and building on the financial recovery in that year, the financial performance monitoring the SHAs and the Department have in place we expect the gross deficits to reduce further in 2007-08.
Anne Milton: To ask the Secretary of State for Health what the cost of implementing the NHS IT programme has been in (a) Surrey primary care trust and (b) England; what assessment her Department has made of the effectiveness of the implementation of the programme; and if she will make a statement. 
Caroline Flint: I refer the hon. Lady to the reply given to my hon. Friend the Member for Birmingham, Sparkbrook and Small Heath (Mr. Godsiff) on 5 March 2007, Official Report, columns 1694-95W; and to those given to the hon. Member for North Norfolk (Norman Lamb) on 12 March 2007, Official Report, column 140W, and on 17 April 2007, Official Report, column 588W.
Mr. Drew: To ask the Secretary of State for Health if she will assess the merits of placing controls on the ability of companies which supply drugs or equipment to the NHS to conduct direct lobbying with patients who receive that service. 
Caroline Flint: There are already controls on companies that supply medicines to the national health service. The Medicines (Advertising) Regulations 1994 prohibit the advertising of prescription only medicines to the public. Any promotion of a prescription only medicine to patients including lobbying activity that may lead to them seeking a prescription from their healthcare provider is likely to fall within this prohibition. Companies may provide non-promotional information, provided they do not promote a specific prescription only medicine.
Products which are defined as medical devices are regulated under the Medical Devices Regulations 2002. The regulations do not cover direct lobbying activities by manufacturers who place medical devices on the market. However, such activities can be dealt with under the Trade Descriptions Act 1968 or the Control of Misleading Advertising Regulations l998.
Ms Rosie Winterton: Targets for representation in local national health service appointments are for 50 per cent. of those appointed to be women, 10 per cent. to be from black and minority ethnic groups and 6 per cent. of those appointed to be disabled.
Mr. Nicholas Brown: To ask the Secretary of State for Health what assessment she has made of the effectiveness of the National Service Framework for (a) cancer, (b) children, (c) chronic obstructive pulmonary disease, (d) coronary heart disease, (e) diabetes, (f) long-term conditions, (g) mental health, (h) older people and (i) renal services in raising standards of care offered to patients. 
Ms Rosie Winterton: The Department has published a number of progress reports looking at the impact of the national service frameworks (NSFs). These are detailed below and are available in the Library:
The NHS Cancer Plan was published in September 2000, and the Department has regularly reviewed progress against it. In October 2003, The NHS Cancer Plan: Three year progress report, Maintaining the momentum, was published and in October 2004, The NHS Cancer Plan and the new NHS: Providing a patient-centred service, was published. In addition, in 2005 the National Audit Office (NAO) published The NHS Cancer Plan: A Progress Report.
The National Service Framework for children, young people and maternity services was published in September 2004. A one-year-on report was produced in 2005. A number of a thematic reports concentrating on particular strands of the NSF have also been produced, most recently a report in November 2006 on the progress made so far on the child and adolescent mental health services (CAMHS) strand.
The chronic obstructive pulmonary disease (COPD) NSF is still under development. The Department is planning to publish the COPD NSF at the end of 2008 with the implementation expected in 2009.
The Department has published regular progress reports on the progress made in implementing the coronary heart disease NSF, most recently Shaping the futureprogress report for 2006. In addition, in 2005 the Healthcare Commission published Getting to the heart of itCoronary heart disease in England: a review of progress towards the national standards.
The NSF Four Years OnThe Way Ahead: The Local ChallengeImproving Diabetes Services has been published. It outlines the progress made in the first four years in implementing the NSF for diabetes.
No assessment has been made of the effectiveness of the Long-term Conditions National Service Framework. There is a 10-year implementation programme for this NSF. The overall pace of change will be according to local priorities and there are no targets. The Department is supporting local health and social care organisations toward implementation through a co-ordinated range of activities.
A comprehensive account of progress made in the first five years of the NSF for mental health is available in the National Director for Mental Healths December 2004 report, The National Service Framework for Mental HealthFive Years On.
A New Ambition for Old Age: Next steps in implementing the National Service Framework for Older People is a refresh of the NSF for older people, and was published in April 2006. This publication was issued at the mid-way point of the 10-year NSF for older people. It built on the progress that had already been made, with older people receiving access to treatment and services in greater numbers than ever before. It sets out the priorities for the next phase of reform under three
main themes: dignity in care, system reform for older people with complex needs, and healthy ageing.
The renal NSF has received positive feedback from the renal community, and the standards and quality requirements set out in it are being delivered. Renal services are managing the ever increasing demand for renal replacement therapy, the number of living kidney donations continues to increase and radical change has been delivered in the areas of early detection of kidney disease and end of life care. A progress report is expected to be published in summer 2007.
Helen Jones: To ask the Secretary of State for Health what steps she is taking to ensure that all health authorities and trusts produce integrated plans for learning and service development as recommended in the recent report by Professor Fryer. 
Ms Rosie Winterton [holding answer 27 February 2007]: The Department is currently assessing the responses to Learning for a Change in Healthcare and expects to be in a position to propose the next steps for implementation of its recommendations by July 2007. The Department has also already ensured that the service level agreement with the strategic health authorities (SHAs) provides a commitment to
provide strategic leadership and, where appropriate, investment to encourage the provision of training and development of the work force and to deliver the recommendations of the Leitch report, Prosperity for all in the global economyworld class skills, and the report of the Widening Participation in Learning Unit, Learning for a change in Healthcare.
plan for the development of the wider work force available and published on the SHA website by 1 September 2007. The plan includes opportunities for income generation and matched funding from Learning and Skills Councils.
Mr. Lansley: To ask the Secretary of State for Health what the rates of obesity amongst adults were in the most recent period for which figures are available, broken down by primary care trust area. 
Caroline Flint: Estimates of prevalence of obesity among adults based on 2000-02 data are presented by primary care organisation (PCO) and this information has been placed in the Library. Primary care organisations represent both primary care trusts, and care trusts.
These estimates represent the prevalence of obesity for any PCO based on population characteristics of that area, together with a statistical model linking population characteristics and obesity levels. The estimates have been generated using a model-based method that combined individual-level data from the Health Survey for England (HSfE) with area-level measures from the 2001 census and from administrative datasets.
The methodology used to produce these estimates is relatively new and as a result may be subject to consultation, modification and further development. In view of this ongoing work the estimates have been published as experimental statistics.
Confidence intervals have been produced to accompany the model-based estimates in order to make the accuracy of the estimates clear. It is important to take into account the variability in the estimates when interpreting them. Therefore, the expected prevalence for a PCO should be viewed in light of its confidence interval rather than just the expected obesity prevalence estimate.
Mr. Ruffley: To ask the Secretary of State for Health what percentage of (a) children and (b) adults are (i) obese and (ii) overweight when measured by body mass index according to the Government's most recent health survey figures in (A) Bury St. Edmunds constituency, (B) Suffolk County Council area, (C) the East of England and (D) England. 
Data on the proportion of men and women who are overweight and obese are available from the HSE 2005. Data on the proportion of men and women who are overweight and obese in the East of England Government Office Region (GOR) has been taken from the HSE 2003, as this year included a sample boost. Data on overweight and obesity prevalence for Suffolk county council are not available. However data for the Norfolk, Suffolk and Cambridgeshire Strategic Health Authority for adults are given and combined for the years 2002 to 2004 due to small sample sizes. Information for Bury St. Edmunds constituency's overweight and obesity prevalence is not available. However, estimated overweight and obesity information is given for Suffolk West Primary Care Trust (PCT) in which Bury St. Edmunds falls.
Data for children's overweight and obesity prevalence in England are available from the 2005 HSE. Data for children's overweight and obesity prevalence in the East of England GOR have been combined for the years 2002 to 2004, due to small sample sizes. Information for children's overweight and obesity prevalence is not available below a regional level.
Mr. Lansley: To ask the Secretary of State for Health how many people were treated for obesity by the NHS in each year since 1997, broken down by the treatment they received; and what the cost was of providing each treatment in the latest period for which figures are available. 
Caroline Flint: Hospital activity and cost information relating to obesity is presented as follows. Figures have been provided on the number of finished consultant episodes (FCEs) with a primary and secondary diagnosis of obesity. Information is also provided on drugs prescribed for the treatment of obesity, including the costs of such drugs. Costs relating specifically to treatment costs for obesity are not available.
Table 2 shows the number of items, net ingredient cost and the average net ingredient cost per item of drugs for the treatment of obesity prescribed in England and dispensed in the community, for the years 2002 to 2006.
|Table 1: Finished consultant episodes( 1) , by primary or secondary diagnosis( 2) of obesity, 1996-97 to 2005-06( 3) , England|
|Primary diagnosis||Secondary diagnosis|
|(1) An FCE is defined as a period of admitted patient care under one consultant within one health care provider.|
(2) ICD-10 code E66 has been used as a diagnosis for obesity.
(3) Figures have not been adjusted for shortfalls in data.
Hospital Episode Statistics, HES. The Information Centre.
|Table 2: Number of items, net ingredient cost and average net ingredient cost per item of drugs for the treatment of obesity prescribed( 1) in England and dispensed in the community, 2002 to 2006, England|
|(1) Includes prescriptions prescribed by GPs, nurses, pharmacists and others in England and dispensed in the community in the UK. Prescriptions written in hospitals/clinics that are dispensed in the community, prescriptions dispensed in hospitals and private prescriptions are not included in PACT data.|
(2) Includes other drugs for the treatment if obesity which include Mazindol, Rimonabant, Phentermine and Diethylpropion Hydrochloride.
Prescribing Analyses and Cost (PACT) from the Prescription Pricing Division of the Business Services Authority (PPD of the BSA).
|Next Section||Index||Home Page|